Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. (January 2015)

• Record Type: Journal Article
• Authors: Feng, Maoxiao; Luo, Xiaochuang; Gu, Chunming; Fei, Jia
• Is Part Of: Journal of drug targeting. Volume 23:Number 1(2015)
• Page Start: 59
• Page End: 66
• Publication Date: 2015-01
• Subjects: Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.3109/1061186X.2014.951653
• Languages: English
• ISSNs: 1061-186X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: miR-155 acts as a ubiquitous oncogene in major classes of human cancers and is a potential target for therapeutic intervention. However, the role of miR-155 in multiple myeloma is poorly understood.</p> <p> <italic>Methods</italic>: To explore the role of miR-155 in multiple myeloma, we assessed the influence of tiny seed-targeting anti-miR-155 (t-anti-miR-155) on multiple myeloma cell line (RPMI-8266) viability and apoptosis <italic>in vitro</italic>.</p> <p> <italic>Results</italic>: t-anti-miR-155 significantly inhibited multiple myeloma cell proliferation, migration, and colony formation. Additionally, t-anti-miR-155 significantly increased CD19 positive cell numbers, which are novel biomarkers for multiple myeloma and suppressor of cytokine signaling 1(SOCS1) was shown to be a target gene for miR-155 in multiple myeloma. Finally, the miR-155 signaling pathway was investigated by KEGG assay.</p> <p> <italic>Conclusion</italic>: miR-155 in RPMI-8266 cells is a critical oncomiR in multiple myeloma and seed-targeting t-anti-miR-155 might be a novel strategy for miR-155-based therapeutics.</p> </abstract>